Changes in risk behaviours during and following treatment for hepatitis C virus infection among people who inject drugs: The ACTIVATE study
Havard Midgard, Behzad Hajarizadeh, Evan B Cunningham, Brian Conway, Markus Backmund, Philip Bruggmann, Julie Bruneau, Stefan Bourgeois, Adrian Dunlop, Graham R Foster, Margaret Hellard, Geert Robaeys, Maria C Thurnheer, Martin Weltman, Janaki Amin, Philippa S Marks, Sophie Quiene, Gregory J Dore, Olav Dalgard, Jason Grebely
International Journal of Drug Policy | ELSEVIER SCIENCE BV | Published : 2017
Awarded by Alberta Innovates
The ACTIVATE study was supported in part by a research grant from the Investigator Initiated Studies Program of Merck Sharp & Dohme Corp. The Opinions expressed in this paper are those of the authors and do not necessarily represent those of Merck Sharp & Dohme Corp. The Kirby Institute is funded by the Australian Government Department of Health. The views expressed in this publication do not necessarily represent the position of the Australian Government. Havard Midgard is supported by research funding from the Norwegian ExtraFoundation for Health and Rehabilitation. Jason Grebely is supported by a National Health and Medical Research Council Career Development Fellowship. Gregory J Dore is supported by a National Health and Medical Research Council Practitioner Research Fellowship. Behzad Hajarizadeh is supported by a National Health and Medical Research Council Early Career Fellowship.